Multicenter Phase II Trial of S-1 Plus Cisplatin in Patients With Untreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- 1 February 2006
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (4) , 663-667
Abstract
Purpose: S-1 plus cisplatin is considered highly active in Japanese gastric cancer patients. We conducted a phase II multi-institutional trial, in the West, in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma to evaluate activity and safety of this combination. Methods: Patients received cisplatin intravenously at 75 mg/m2 on day 1 and S-1 orally at 25 mg/m2/dose bid (50 mg/m2/d) on days 1 to 21, repeated every 28 days. Patients with histologic proof of gastric or gastroesophageal junction adenocarcinoma with a Karnofsky performance status (KPS) of ≥ 70% and near-normal organ function were eligible. All patients provided a written informed consent. To observe a 45% confirmed overall response rate (ORR), 41 assessable patients were needed. Results: All 47 patients were assessed for safety and survival, and 41 patients were assessed for ORR. The median age was 56 years and median KPS was 80%. The median number of chemotherapy cycles was four. The confirmed ORR was 51% (95% CI, 35% to 67%) and it was 49% by an independent review. At the 6-month interval, 71% of patients were alive, with a median survival time of 10.9 months. Frequent grade 3 or 4 toxicities included fatigue (26%), neutropenia (26%), vomiting (17%), diarrhea (15%), and nausea (15%); however, stomatitis (2%) and febrile neutropenia (2%) were uncommon. There was one (2%) treatment-related death. Conclusion: S-1 plus cisplatin is active against gastric cancer and has a favorable toxicity profile. A global phase III study of S-1 plus cisplatin versus fluorouracil plus cisplatin currently is accruing patients.Keywords
This publication has 14 references indexed in Scilit:
- Phase I Pharmacokinetic Study of S-1 Plus Cisplatin in Patients With Advanced Gastric CarcinomaJournal of Clinical Oncology, 2005
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancerBritish Journal of Cancer, 2003
- Phase II trial with S-1 in chemotherapy-naı̈ve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG)European Journal of Cancer, 2003
- Phase I Clinical and Pharmacokinetic Study of Oral S-1 in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2000
- Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric CancerOncology, 2000
- Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patientsEuropean Journal of Cancer, 1998
- Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in ratsCancer Chemotherapy and Pharmacology, 1996
- Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulatorsAnti-Cancer Drugs, 1996
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989